Ideaya Biosciences reported that its uveal melanoma program cleared an internal success benchmark in a late-stage open-label trial. The company said the results strengthen expectations for an accelerated FDA filing in the US. The study targeted a rare ocular malignancy where timely options are limited and regulatory pathways can hinge on endpoint performance. Passing the company’s benchmark positions the program for the next regulatory and discussion steps with US regulators. Investors and clinicians will now watch for the filing timeline, confirmatory data expectations, and how the efficacy signal translates into a practical label strategy.